Rexulti

Pharma

How Lundbeck’s CEO aims to keep firm ‘punching above its weight’

Lundbeck’s CEO, Charl van Zyl, told Fierce that he is confident the company can prove its mettle as a “neuroscience challenger.”

Fraiser Kansteiner Aug 21, 2026 11:30am

more expensive

Axsome increases Auvelity's peak sales projection to $8B

May 5, 2026 11:48am

Go sign green light

Axsome's Auvelity wins FDA expansion for Alzheimer's agitation

May 1, 2026 11:42am

Lundbeck

After Avadel setback, Lundbeck signals future M&A rigor

Jan 22, 2026 11:13am

brain amyloid alzheimers strings detailed web complicated thought

Lundbeck, Otsuka back survey on Alzheimer's agitation

Nov 12, 2025 12:07pm

football tv remote

TV drug ad spending picked up in September despite crackdown

Oct 7, 2025 6:25am